1600-0404/asset/ane_centre.gif?v=1&s=9cea22b5a9e4a043392f019cd5a2786e79a1384a)
Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort
Article first published online: 4 JUL 2007
DOI: 10.1111/j.1600-0404.2007.00872.x
Additional Information
How to Cite
Greeve, I., Sellner, J., Lauterburg, T., Walker, U., Rösler, K. M. and Mattle, H. P. (2007), Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurologica Scandinavica, 116: 207–210. doi: 10.1111/j.1600-0404.2007.00872.x
Publication History
- Issue published online: 4 JUL 2007
- Article first published online: 4 JUL 2007
- Accepted for publication March 12, 2007
- Abstract
- Article
- References
- Cited By
Keywords:
- clinically isolated syndrome;
- multiple sclerosis;
- anti-myelin oligodendrocyte glycoprotein;
- anti-myelin basic protein;
- β-interferon;
- Swiss cohort
Objectives – In patients with a clinically isolated syndrome (CIS), the time interval to convert to clinically definite multiple sclerosis (CDMS) is highly variable. Individual and geographical prognostic factors remain to be determined. Whether anti-myelin antibodies may predict the risk of conversion to CDMS in Swiss CIS patients of the canton Berne was the subject of the study.
Methods – Anti-myelin oligodendrocyte glycoprotein and anti-myelin basic protein antibodies were determined prospectively in patients admitted to our department.
Results – After a mean follow-up of 12 months, none of nine antibody-negative, but 22 of 30 antibody-positive patients had progressed to CDMS. β-Interferon treatment delayed the time to conversion from a mean of 7.4 to 10.9 months.
Conclusions – In a Swiss cohort, antibody-negative CIS patients have a favorable short-term prognosis, and antibody-positive patients benefit from early treatment.